share_log

6-K: Report of foreign private issuer (related to financial reporting)

6-K: Report of foreign private issuer (related to financial reporting)

6-K：外国发行人报告（业绩相关）
美股SEC公告 ·  2024/08/31 03:53

Moomoo AI 已提取核心信息

TC BioPharm completed an upsized public offering on August 29, 2024, raising $6 million in gross proceeds. The offering included 53,558 American Depositary Shares (ADSs), pre-funded warrants to purchase up to 5,946,442 ADSs, and series H warrants to purchase up to 6,000,000 ADSs, priced at $1.00 per ADS and associated warrant.The Series H Warrants are immediately exercisable with a one-year expiration period and an exercise price of £0.76 ($1.00) per ADS. The pre-funded warrants are exercisable at $0.001 per ADS until fully exercised. Each ADS represents 200 ordinary shares of the company.The proceeds will support TC BioPharm's upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, market awareness initiatives, and ongoing operational expenses. The offering was conducted under an effective registration statement filed with the SEC on Form F-1.
TC BioPharm completed an upsized public offering on August 29, 2024, raising $6 million in gross proceeds. The offering included 53,558 American Depositary Shares (ADSs), pre-funded warrants to purchase up to 5,946,442 ADSs, and series H warrants to purchase up to 6,000,000 ADSs, priced at $1.00 per ADS and associated warrant.The Series H Warrants are immediately exercisable with a one-year expiration period and an exercise price of £0.76 ($1.00) per ADS. The pre-funded warrants are exercisable at $0.001 per ADS until fully exercised. Each ADS represents 200 ordinary shares of the company.The proceeds will support TC BioPharm's upcoming clinical trial focusing on relapse/refractory Acute Myeloid Leukemia, market awareness initiatives, and ongoing operational expenses. The offering was conducted under an effective registration statement filed with the SEC on Form F-1.
TC BioPharm于2024年8月29日完成了一次增大的公开募股，筹集了600万美元的总收益。此次募股包括53,558个美国存托股票（ADS）、预授权购买最多5,946,442个ADS的Warrants，以及购买最多6,000,000个ADS的H系列Warrants，价格为每个ADS和相关Warrant $1.00。H系列Warrants可立即行使，期限为一年，行使价格为每个ADS £0.76（$1.00）。预授权Warrants可在0.001美元每个ADS的价格下行使，直到完全行使。每个ADS代表200股公司的普通股。筹集的资金将支持TC BioPharm即将开展的临床试验，专注于复发/难治性急性髓系白血病、市场宣传活动以及持续的运营支出。此次募股是在根据SEC提交的F-1表格的有效登记声明下进行的。
TC BioPharm于2024年8月29日完成了一次增大的公开募股，筹集了600万美元的总收益。此次募股包括53,558个美国存托股票（ADS）、预授权购买最多5,946,442个ADS的Warrants，以及购买最多6,000,000个ADS的H系列Warrants，价格为每个ADS和相关Warrant $1.00。H系列Warrants可立即行使，期限为一年，行使价格为每个ADS £0.76（$1.00）。预授权Warrants可在0.001美元每个ADS的价格下行使，直到完全行使。每个ADS代表200股公司的普通股。筹集的资金将支持TC BioPharm即将开展的临床试验，专注于复发/难治性急性髓系白血病、市场宣传活动以及持续的运营支出。此次募股是在根据SEC提交的F-1表格的有效登记声明下进行的。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Moleculin Biotech
    MBRX
    -- 2.1800
    Allogene Therapeutics
    ALLO
    -- 2.040
    CNS Pharmaceuticals
    CNSP
    -- 0.1400
    Tenaya Therapeutics
    TNYA
    -- 1.200
    LEXARIA BIOSCIENCE CORP C/WTS(TO PUR COM)
    LEXXW
    -- 0.3400
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    多家机构看多！中国资产将全面重估：你会如何布局？
    近期，Goldman Sachs、Morgan Stanley、Appaloosa LP等多家机构唱好中国资产。 🎙️讨论： 1. Deepseek引爆中国资产上涨，后市你怎么看？ 2. 多家中国企业1月表现提升，你更看好谁？ 展开
    中国的资产重估引发了讨论：mooer们在买什么？